Company profile for Q32 Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Q32 Bio has advanced a strong clinical and discovery pipeline based on the body’s innate and adaptive immune systems and the drive to restore immune homeostasis in patients with severe inflammatory and autoimmune diseases. With an expert team comprised of highly skilled drug developers and immunology experts from the biotech/biopharma industry, Q32 Bio is well-positioned to deliver on its mission to bring new therapeutics to...
Q32 Bio has advanced a strong clinical and discovery pipeline based on the body’s innate and adaptive immune systems and the drive to restore immune homeostasis in patients with severe inflammatory and autoimmune diseases. With an expert team comprised of highly skilled drug developers and immunology experts from the biotech/biopharma industry, Q32 Bio is well-positioned to deliver on its mission to bring new therapeutics to patients with severe inflammatory and autoimmune diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
One Broadway, 11th Floor, Cambridge, MA 02142
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/01/3196841/37519/en/Akebia-Announces-Establishment-of-Rare-Kidney-Disease-Pipeline.html

GLOBENEWSWIRE
01 Dec 2025

https://www.prnewswire.com/news-releases/q32-bio-reports-third-quarter-2025-financial-results-and-provides-corporate-update-302613664.html

PR NEWSWIRE
13 Nov 2025

https://www.prnewswire.com/news-releases/q32-bio-announces-completion-of-enrollment-in-part-b-of-signal-aa-phase-2a-clinical-trial-of-bempikibart-for-alopecia-areata-302589401.html

PR NEWSWIRE
21 Oct 2025

https://www.prnewswire.com/news-releases/q32-bio-to-participate-in-the-2025-wells-fargo-healthcare-conference-302540421.html

PR NEWSWIRE
28 Aug 2025

https://www.prnewswire.com/news-releases/q32-bio-reports-second-quarter-2025-financial-results-and-provides-corporate-update-302523044.html

PR NEWSWIRE
07 Aug 2025

https://www.prnewswire.com/news-releases/q32-bio-appoints-adrien-sipos-md-phd-as-interim-chief-medical-officer-302490343.html

PR NEWSWIRE
25 Jun 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty